Actively Recruiting
Prediction of LVAR and MACE in STEMI Though Plasma Multiomics Analysis
Led by Beijing Anzhen Hospital · Updated on 2026-05-12
1000
Participants Needed
1
Research Sites
139 weeks
Total Duration
On this page
Sponsors
B
Beijing Anzhen Hospital
Lead Sponsor
B
Beijing Jishuitan Hospital
Collaborating Sponsor
AI-Summary
What this Trial Is About
To identify plasma multi-omics biomarkers that predict left ventricular adverse remodeling (LVAR) and major adverse cardiovascular events (MACE) in patients with acute ST-segment elevation myocardial infarction, and to investigate the molecular pathways linked to LVAR and MACE.
CONDITIONS
Official Title
Prediction of LVAR and MACE in STEMI Though Plasma Multiomics Analysis
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 to 80 years
- Confirmed diagnosis of STEMI based on ESC/ACC guidelines, including chest pain lasting more than 30 minutes and specific ST-segment elevation criteria or new left bundle branch block
- Symptom onset to first medical contact within 12 hours, followed by successful primary PCI with restored blood flow
- First occurrence of STEMI; no prior myocardial infarction
- Left ventricular ejection fraction of 35% or higher measured by echocardiography within 24-48 hours after admission
- Signed informed consent and willingness to undergo serial blood sampling and echocardiographic follow-up
You will not qualify if you...
- Non-atherosclerotic myocardial infarction causes such as coronary embolism, spasm, aortic dissection, myocarditis, or Takotsubo syndrome
- Severe comorbid conditions including prior heart failure (NYHA class II or higher), severe chronic kidney disease (eGFR below 30 or dialysis), severe liver disease (Child-Pugh B/C), active cancer with life expectancy under 1 year, and serious blood disorders
- Treatment involving fibrinolysis followed by PCI
- Complications from primary PCI such as no-reflow or slow-flow (final TIMI grade below 2), cardiogenic shock or mechanical complications within 7 days, or repeat revascularization during hospital stay
- Inability to complete six-month follow-up
- Factors interfering with blood sampling or molecular assays, including recent blood transfusion (within 1 month), known hemolytic disorders, or inadequate venous access
- Pregnancy or lactation
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Beijing Anzhen Hospital, Capital Medical University.
Beijing, Beijing Municipality, China, 100029
Actively Recruiting
Research Team
X
Xu Wang, Dr.
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here